ArticleEClinicalMedicine2022

Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.

Yuemiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.